Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Although the demand for COVID-19 vaccines has waned ... could be a costly speed bump. Without a doubt, the outcome of this IP battle will be critical to Moderna's clinical and commercial future.

Watertown, Mass., added millions of square feet of lab space in just a few years. Here's how it happened, and why the pace ...

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

The lump can be a good sign that the body is making antibodies ... It is more common after the Moderna vaccine and causes redness, itching, and swelling around the injection site. COVID arm rash ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

GSK claims Moderna used its patented mRNA vaccine platform without a license, reaping billions from vaccine sales. The Mandl team at GSK developed a pioneering mRNA platform that has set the ...